Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826870 | 0.93 | HRH1 (0.62) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL826729 | 0.92 | HRH1 (0.62) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12045388 | 0.91 | HRH1 (0.65) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12045400 | 0.91 | HRH1 (0.61) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12045412 | 0.90 | HRH1 (0.63) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12930665 | 0.90 | HRH1 (0.59) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL19114794 | 0.90 | HRH1 (0.61) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12045377 | 0.89 | HRH1 (0.62) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12045392 | 0.89 | HRH1 (0.63) | HRH1CYP2D6KCNH2CHRM1ADRA2A | |
| SCHEMBL12045390 | 0.88 | HRH1 (0.69) | HRH1CYP2D6KCNH2CHRM1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2015-11-12 | — | — | US | disclosed |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2015-11-12 | — | — | US | disclosed |
| US-9072788-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-07 | — | — | US | disclosed |
| US-9072788-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-07 | — | — | US | disclosed |
| WO-2011163594-A2 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | HRH1 620/4885CYP2D6 654/4885KCNH2 2776/4885 |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | HRH1 620/4885CYP2D6 654/4885KCNH2 2776/4885 |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | PHPT1, SI, CA6 | HRH1 620/4885CYP2D6 654/4885KCNH2 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.